Sarepta therapeutics and dyno therapeutics announce agreement to develop next-generation gene therapy vectors for muscle diseases

Sarepta therapeutics and dyno therapeutics announce agreement to develop next-generation gene therapy vectors for muscle diseases.sarepta therapeutics - agreement to develop next-generation adeno-associated virus vectors for muscle diseases, using dyno's capsidmap platform.sarepta therapeutics - dyno will be responsible for design and discovery of novel aav capsids.sarepta therapeutics - if successful, dyno could receive over $40 million in upfron.sarepta therapeutics - dyno will receive royalties on worldwide net sales of any commercial products developed.
SRPT Ratings Summary
SRPT Quant Ranking